Advertisement

Topics

AstraZeneca's Fasenra Approved By FDA For Severe Eosinophilic Asthma

08:59 EST 15 Nov 2017 | Pharmaceutical Processing

Fasenra distinctively targets and rapidly depletes eosinophils and is the first respiratory biologic with an 8-week maintenance dosing schedule.
Contributed Author: 
AstraZeneca

Original Article: AstraZeneca's Fasenra Approved By FDA For Severe Eosinophilic Asthma

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca's Fasenra Approved By FDA For Severe Eosinophilic Asthma"

Advertisement
Quick Search
Advertisement
Advertisement